Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Broad Center for Mendelian Genomics, |
RCV001004906 | SCV001164406 | likely pathogenic | Hereditary spherocytosis type 2 | 2018-12-03 | criteria provided, single submitter | research | The heterozygous p.Ser2019Pro variant in SPTB was identified by our study in three unrelated individuals with spherocytosis. This variant was absent from large population studies. Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. The p.Ser2019Pro variant in SPTB has been reported in 8 Laotian individuals with spherocytosis and segregated with disease in the homozygous or heterozygous state in 7 affected relatives from a two-generation family. The genotype of one affected individual was unknown. All individuals known to be homozygous for the variant were stillborn or died shortly after birth while all individuals known to be heterozygous for the variant had mild elliptocytosis (PMID: 7883966). This variant is located in the self-association region of the protein, a common site of pathogenic variation for hereditary elliptocytosis (PMID: 8844207). In summary, although additional studies are required to fully establish its clinical significance, the p.Ser2019Pro variant is likely pathogenic. ACMG/AMP Criteria applied: PM1, PM2, PP1_Moderate (Richards 2015). |
Labcorp Genetics |
RCV002513020 | SCV003442308 | pathogenic | not provided | 2024-05-12 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with proline, which is neutral and non-polar, at codon 2019 of the SPTB protein (p.Ser2019Pro). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with hereditary elliptocytosis and/or neonatal nonimmune hemolytic anemia (PMID: 7883966, 30198572). It has also been observed to segregate with disease in related individuals. This variant is also known as spectrin Providence. ClinVar contains an entry for this variant (Variation ID: 12837). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects SPTB function (PMID: 7883966, 8667615). For these reasons, this variant has been classified as Pathogenic. |
Revvity Omics, |
RCV002513020 | SCV003827413 | pathogenic | not provided | 2022-03-14 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000013688 | SCV000033935 | pathogenic | Elliptocytosis 3 | 2018-04-25 | no assertion criteria provided | literature only | |
Prevention |
RCV004724739 | SCV005339608 | pathogenic | SPTB-related disorder | 2024-09-12 | no assertion criteria provided | clinical testing | The SPTB c.6055T>C variant is predicted to result in the amino acid substitution p.Ser2019Pro. This variant is also referred to as spectrin Providence and has been noted to be common in individuals with severe inherited hemolytic anemia in the Thai population (Ittiwut et al. 2019. PubMed ID: 30198572; Songdej et al. 2024. PubMed ID: 35819869). It has been reported in the homozygous and compound heterozygous states in individuals with severe inherited hemolytic anemia (Gallagher et al. 1995. PubMed ID: 7883966; Ittiwut et al. 2019. PubMed ID: 30198572; Songdej et al. 2024. PubMed ID: 35819869). Individuals heterozygous for this variant have been reported to have a milder elliptocytosis phenotype (Gallagher et al. 1995. PubMed ID: 7883966; Songdej et al 2024. PubMed ID: 35819869). In vitro experimental studies indicate this variant impacts protein function (Gallagher et al. 1995. PubMed ID: 7883966; Weed et al. 1996. PubMed ID: 8667615). This variant has not been reported in a large population database, indicating this variant is rare. This variant is interpreted as pathogenic. |